These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32121)

  • 41. Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.
    Koch G
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):725-8. PubMed ID: 10950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Interaction of labetalol with alpha- and beta-adrenergic receptors : biochemical study (author's transl)].
    Dausse JP; Guicheney P; Maich PJ; Meyer P
    Nouv Presse Med; 1978 Oct; 7(35):3121-3. PubMed ID: 31601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Labetalol. Current research and therapeutic status.
    Wallin JD; O'Neill WM
    Arch Intern Med; 1983 Mar; 143(3):485-90. PubMed ID: 6338850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.
    Kornerup HJ; Pedersen EB; Christensen NJ; Pedersen A; Pedersen G
    Eur J Clin Pharmacol; 1979 Nov; 16(5):305-10. PubMed ID: 520398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biochemical evidence for the dual action of labetalol on alpha- and beta-adrenoceptors.
    Aggerbeck M; Guellaen G; Hanoune J
    Br J Pharmacol; 1978 Apr; 62(4):543-8. PubMed ID: 26446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Combined alpha and beta adrenergic receptor blockade in the treatment of renal hypertension].
    Stummvoll HK
    Wien Med Wochenschr Suppl; 1981; 69():14-6. PubMed ID: 6123200
    [No Abstract]   [Full Text] [Related]  

  • 47. [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient].
    Sassard J; Zech PY; Pozet N; Cuisinaud G; Vincent M
    J Pharmacol; 1983; 14 Suppl 2():121-9. PubMed ID: 6355664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Labetalol, a new alpha- and beta-adrenoreceptor blocking agent, in hypertension.
    Hansson L; Hänel B
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):763-4. PubMed ID: 10952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adrenoceptor blocking drugs: clinical pharmacology and therapeutic use.
    McDevitt DG
    Drugs; 1979 Apr; 17(4):267-88. PubMed ID: 37065
    [No Abstract]   [Full Text] [Related]  

  • 50. Labetalol for hypertension.
    Med Lett Drugs Ther; 1984 Sep; 26(670):83-5. PubMed ID: 6147747
    [No Abstract]   [Full Text] [Related]  

  • 51. Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals.
    Kennedy I; Levy GP
    Br J Pharmacol; 1975 Apr; 53(4):585-92. PubMed ID: 238705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Some complementary data on AH 5158, an inhibitor of both alpha-and beta-adrenoceptors [proceedings].
    Harichaux P; Hary L
    Br J Pharmacol; 1976 Nov; 58(3):412P. PubMed ID: 11020
    [No Abstract]   [Full Text] [Related]  

  • 53. Systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress test responses.
    Prida XE; Hill JA; Feldman RL
    Am J Cardiol; 1987 May; 59(12):1084-8. PubMed ID: 2883869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of labetalol with other anti-hypertensive drugs.
    Prichard BN; Richards DA
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):41S-47S. PubMed ID: 6124265
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacological effects of labetalol in man.
    Richards DA
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):721-3. PubMed ID: 10949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Arylethanolamines derived from salicylamide with alpha- and beta-adrenoceptor blocking activities. Preparation of labetalol, its enantiomers, and related salicylamides.
    Clifton JE; Collins I; Hallett P; Hartley D; Lunts LH; Wicks PD
    J Med Chem; 1982 Jun; 25(6):670-9. PubMed ID: 6124636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effects of labetalol on the circulatory system (author's transl)].
    Monma Y; Okuoka Y; Kameda H; Ichihara K; Abiko Y; Tanabe T
    Nihon Yakurigaku Zasshi; 1980 May; 76(4):239-54. PubMed ID: 6108907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension.
    Rosei EA; Brown JJ; Fraser R; Lever AF; Morton JJ; Robertson JI; Trust PM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):83-8. PubMed ID: 14627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.
    Pearson RM; Havard CW
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):795-8. PubMed ID: 10953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of an alpha- and beta-adrenoceptor-blocking agent (labetalol) on haemodynamics in hypertension.
    Bahlmann J; Brod J; Hubrich W; Cachovan M; Pretschner P
    Br J Clin Pharmacol; 1979; 8(Suppl 2):113S-117S. PubMed ID: 526390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.